TABLE 1.
Patient and tumor characteristics, based on preoperative NLR, of patients who underwent esophagectomy for esophageal cancer, 1996–2009
| Low NLR (n = 239) |
High NLR (n = 56) |
P value | |
|---|---|---|---|
| Mean age, years (± SD) | 62.8 (±11.1) | 62.8 (±12.6) | 0.50 |
| Sex, male | 191 (79.9%) | 46 (82.1%) | 0.85 |
| Race/ethnicity | 0.44 | ||
| White | 212 (88.7%) | 49 (96.1%) | |
| Black | 5 (2.1%) | 1 (1.9%) | |
| Asian | 18 (7.5%) | 1 (1.9%) | |
| Hispanic | 4 (1.7%) | 0 | |
| Stage | 0.90 | ||
| 1 | 41 (17.5%) | 9 (16.7%) | |
| 2 | 73 (30.5%) | 19 (33.9%) | |
| 3 | 105 (43.9 %) | 24 (42.9%) | |
| 4 | 20 (8.4%) | 4 (7.4%) | |
| Histology | 0.67 | ||
| Adenocarcinoma | 171 (71.9%) | 43 (76.7%) | |
| Squamous | 63 (26.3%) | 12 (21.4%) | |
| Othera | 3 (1.3%) | 1 (1.79%) | |
| Tumor subsite | 0.19 | ||
| GE junction, lower | 190 (79.6%) | 49 (87.5) | |
| Mid, upper | 49 (20.5) | 7 (12.5) | |
| Neoadjuvant treatment | 95 (39.7%) | 32 (57.1%) | 0.02 |
| Tumor differentiation | 0.57 | ||
| Well | 22 (9.2%) | 6 (10.7%) | |
| Moderate | 124 (51.2%) | 23 (41.1%) | |
| Poor | 93 (38.9%) | 24 (42.8%) | |
| Aspirin/NSAID use | 58 (23.1%) | 15 (26.3%) | 0.36 |
| Smoking history, ever | 175 (73.2%) | 43 (76.7%) | 0.74 |
| Comorbidities | 0.75 | ||
| 0 | 196 (82.0%) | 46 (82.1%) | |
| 1 | 38 (15.9%) | 10 (17.8%) | |
| >1 | 5 (2.1%) | 0 |
a
Other (small cell = 2, GIST = 1, undifferentiated = 1)